<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Burns Trauma</journal-id><journal-id journal-id-type="iso-abbrev">Burns Trauma</journal-id><journal-title-group><journal-title>Burns &#x00026; Trauma</journal-title></journal-title-group><issn pub-type="ppub">2321-3868</issn><issn pub-type="epub">2321-3876</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27574654</article-id><article-id pub-id-type="pmc">4964106</article-id><article-id pub-id-type="publisher-id">6</article-id><article-id pub-id-type="doi">10.1186/s41038-015-0006-8</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Mannitol cannot reduce the mortality on acute severe traumatic brain injury (TBI) patients: a meta&#x02013;analyses and systematic review</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Wang</surname><given-names>Kai</given-names></name><address><email>371352604@qq.com</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Sun</surname><given-names>Mingwei</given-names></name><address><email>sunmw@medmail.com.cn</email></address><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Jiang</surname><given-names>Hua</given-names></name><address><email>hua.jiang@traumabank.org</email></address><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Cao</surname><given-names>Xiao-ping</given-names></name><address><email>1792847214@qq.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Zeng</surname><given-names>Jun</given-names></name><address><email>zengjun@medmail.com.cn</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><aff id="Aff1"><label>1</label>Department of Emergency Medicine, Affiliated Hospital of North Sichuan Medical College, Nanchong, 637000 P. R. China </aff><aff id="Aff2"><label>2</label>Department of Computational Mathematics and Biological Statistics, Metabolomics and Multidisciplinary Laboratory for Trauma Research, Institute for Emergency and Disaster Medicine, Sichuan Provincial People&#x02019;s Hospital, Sichuan Academy of Medical Sciences, Chengdu, 610101 P. R. China </aff><aff id="Aff3"><label>3</label>Department of Acute Care Surgery, Sichuan Provincial People&#x02019;s Hospital, Sichuan Academy of Medical Sciences, Chengdu, 610073 P. R. China </aff></contrib-group><pub-date pub-type="epub"><day>5</day><month>6</month><year>2015</year></pub-date><pub-date pub-type="pmc-release"><day>5</day><month>6</month><year>2015</year></pub-date><pub-date pub-type="collection"><year>2015</year></pub-date><volume>3</volume><elocation-id>8</elocation-id><history><date date-type="received"><day>5</day><month>5</month><year>2015</year></date><date date-type="accepted"><day>5</day><month>5</month><year>2015</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2015</copyright-statement><license license-type="open-access"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p>We aimed to systematically review the efficacy of mannitol (MTL) on patients with acute severe traumatic brain injury (TBI).</p></sec><sec><title>Methods</title><p>Databases such as PubMed (US National Library of Medicine), CENTRAL (The Cochrane Library 2014, Issue 3), ISI (Web of Science: Science Citation Index Expanded), Chinese Biomedicine Database (CBM), and China Knowledge Resource Integrated Database (CNKI) have been searched for relevant studies published between 1 January 2003 and 1 October 2014. We have established inclusion and exclusion criteria to identify RCTs, which were suitable to be enrolled in the systematic review. The comparison group could be hypertonic saline (HS), hydroxyethyl starch, or others. The quality assessment was based on the Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 and modified Jadad score scale. The major outcome was mortality, followed by the secondary outcomes such as neurological outcome, days on intensive care unit (ICU), and ventilator day. In addition, intracranial pressure (ICP), cerebral perfusion pressure (CPP), and mean arterial pressure (MAP) were used as the surrogate endpoints. Data synthesis and meta-analysis was conducted by using R (version 3.7-0.).</p></sec><sec><title>Results</title><p>When 176 potential relevant literatures and abstracts have been screened, four RCTs met all the inclusion criteria and were enrolled for the meta-analysis. Amongst all the enrolled studies, two trials have provided the primary outcome data. There was no heterogeneity between two studies (<italic>I</italic><sup>2</sup>&#x02009;=&#x02009;0&#x000a0;%) and a fixed model was used for meta-analysis (<italic>n</italic>&#x02009;=&#x02009;53), pooled result indicated that the mortality was similar in mannitol intervention and control treatment, OR&#x02009;=&#x02009;0.80, 95&#x000a0;% CI [0.27, 2.37], <italic>P</italic>&#x02009;=&#x02009;0.38. We found that both mannitol and HS were efficient in decreasing the ICP. Furthermore, the effect of the HS on the ICP appeared to be more effective in the patients with diffuse brain injuries than mannitol did.</p></sec><sec><title>Conclusions</title><p>As a conclusion, the mannitol therapy cannot reduce the mortality risk of acute severe traumatic brain injury. Current evidence does not support the mannitol as an effective treatment of acute severe traumatic brain injury. The well-designed randomized controlled trials are in urgent need to demonstrate the adoption of mannitol to acute severe traumatic brain injury.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Mannitol</kwd><kwd>TBI</kwd><kwd>Systematic review</kwd><kwd>Meta-analysis</kwd><kwd>Mortality</kwd><kwd>Intracranial pressure (ICP)</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2015</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Background</title><p>Dehydration treatment is one of the main interventions that are adopted to prevent herniation of intracranial hypertension. Mannitol is widely used in China as a dehydrating agent in traumatic brain injury (TBI) patients with intracranial hypertension. Earlier studies indicated that dehydration therapy might decrease the intracranial pressure (ICP) of patients with TBI by reducing cerebral edema [<xref ref-type="bibr" rid="CR1">1</xref>]. However, the excessive dosage of mannitol will penetrate from the blood into the brain, where it might cause the increase of the intracranial pressure (rebound phenomenon) and introduce the secondary brain cells damage accordingly [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR3">3</xref>]. Therefore, the effectiveness of the treatment of mannitol for the intracranial hypertension in TBI is controversial [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>]. After the 1990s, a few new dehydration products have been introduced as the ICP reduction mediums, such as the hypertonic saline (HS) and the colloidal solution. Some clinical trials have shown that the hypertonic saline is more effective than mannitol in reducing the intracranial pressure and increase the cerebral perfusion pressure [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR6">6</xref>]. However, there are studies with various results and conclusions [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>]. Single clinical trial usually has disadvantages by its sample size, design, or conduction. Clinical practitioners are puzzled by the chaos of the conflicted evidences and opinions to this end. The widespread use of mannitol is in great need of clarity optimal administration. There is uncertainty over the effectiveness of mannitol when compared to other ICP-lowering agents and other treatment without dehydrating agents. As a result, a systematic review is in urgent need, and this is why we present this study.</p></sec><sec id="Sec2" sec-type="materials|methods"><title>Methods</title><sec id="Sec3"><title>Strategy of data retrieving</title><p>Published literatures on the use of mannitol in severe traumatic brain injury patients were retrieved in the following databases: PubMed (US National Library of Medicine), The Cochrane Library (2014, Issue 3), ISI (Web of Science: Science Citation Index Expanded), Chinese Biomedicine Database (CBM), and China Knowledge Resource Integrated Database (CNKI). Letters have been sent to the first authors of the reports, asking them to assist in identifying any further trials that may have been conducted by them but not been reported publicly. Eligibility was determined by reading the reports of possible trials. The terms and strategies of retrieving are listed in the Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Search terms and search strategy</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Database</th><th>Searched items</th><th>Search strategy</th></tr></thead><tbody><tr><td rowspan="3">PubMed</td><td>1. (Mannitol OR Mannit OR Mannite OR Osmosal OR Osmosteril OR Resectisol OR Aridol OR Bronchitol)</td><td>#1 AND #2 AND #3</td></tr><tr><td>2. (&#x0201c;intracranial pressure&#x0201d; OR &#x0201c;intracranial hypotension&#x0201d; OR &#x0201c;intracranial hypertension&#x0201d; OR brain)</td><td/></tr><tr><td>3.((randomized controlled trial[pt] OR controlled clinical trial[pt]OR (&#x0201c;Clinical Trials as Topic&#x0201d; [MeSH Major Topic])) NOT ((&#x0201c;Animals&#x0201d; [MeSH]) NOT (&#x0201c;Humans&#x0201d; [MeSH] AND &#x0201c;Animals&#x0201d; [MeSH]))</td><td/></tr><tr><td rowspan="3">ISI</td><td>1. Topic&#x02009;=&#x02009;(mannitol or Mannit or Mannite or Osmosal or Osmosteril or Resectisol or Aridol or Bronchitol)</td><td>1 and 2 and 3</td></tr><tr><td>2. Topic&#x02009;=&#x02009;(intracranial pressure OR intracranial hypotension OR intracranial hypertension OR brain*)</td><td/></tr><tr><td>3. TS&#x02009;=&#x02009;(clinical OR control* OR placebo OR random OR randomised OR randomized OR randomly OR random order OR random sequence OR random allocation OR randomly allocated OR at random)</td><td/></tr><tr><td rowspan="4">Cochrane</td><td>1.(mannitol OR Manit OR Mannite or Osmosal or Osmosteril or Resectisol or Aridol or Bronchitol)</td><td>1AND (2 OR 3 OR 4)</td></tr><tr><td>2. &#x0201c;intracranial pressure&#x0201d;</td><td/></tr><tr><td>3. &#x0201c;intracranial hypotension&#x0201d;</td><td/></tr><tr><td>4. &#x0201c;intracranial hypertension&#x0201d;</td><td/></tr><tr><td>CBM</td><td>1. &#x0201c;mannitol&#x0201d; [Full field] 2. &#x0201c;mannitol&#x0201d; [MeSH])&#x0201d; 3. brain injury&#x0201d; [Full field] 4. &#x0201c;Head injury&#x0201d; [MeSH] 5. &#x0201c;Parietal damage&#x0201d; [Full field] 6. &#x0201c;Frontal damage&#x0201d; [Full field] 7. &#x0201c;Temporal damage&#x0201d; [Full field] 8. &#x0201c;Head injury&#x0201d; [Full field] 9. &#x0201c;Occipital damage&#x0201d; [Full field] 10. &#x0201c;Brain Injury&#x0201d; [MeSH] 11. &#x0201c;intracranial hypotension&#x0201d; [Full field] 12. &#x0201c;intracranial hypotension&#x0201d; [MeSH] 13. &#x0201c;Animal experiments&#x0201d; [Full field] 14. &#x0201c;Animal experiments&#x0201d; [MeSH]</td><td>(1 OR 2) AND (3 OR 4 OR 5 OR 6 OR 7 OR 8 OR 9 OR 10) AND (11 OR 12) NOT (13 OR 14)</td></tr><tr><td>CNKI</td><td>1. KY&#x02009;=&#x02009;mannitol 2. KY&#x02009;=&#x02009;brain injury 3. KY&#x02009;=&#x02009;intracranial hypotension 4. KY&#x02009;=&#x02009;animals</td><td>1 AND 2 AND 3 NOT 4</td></tr></tbody></table></table-wrap></p><sec id="Sec4"><title>Inclusion criteria</title><p>Studies evaluating adult trauma patients with severe traumatic brain injuries and which included mannitol as an intervention were evaluated. The following data were required for inclusion: (1) study design: only RCTs set up with parallel control groups were selected, excluding self-control or crossover trials;(2) type of patients: adult trauma patients (age &#x02265;18&#x000a0;years); (3) severe brain injures (Glasgow coma score &#x0003c;8) with cerebral edema. When indexes of the two groups such as genders, ages, pre-treatment ICP, osmolality levels, and Glasgow scores were matched, then the two groups were comparable; (4) intervention: the treatment group received mannitol in any dose for any duration, while the comparison group could be placebo controlled, different dose, different agent, or no agent; (5) reported one or more outcomes as following: (a) primary outcome: the mortality and (b) secondary outcome: (i) days on ICU and (ii) ventilator day; and (6) surrogate endpoints: ICP, cerebral perfusion pressure (CPP), and mean arterial pressure (MAP). The mortality is related with secondary and surrogate outcomes, so we collect them in the study.</p></sec><sec id="Sec5"><title>Exclusion criteria</title><p>The following data were required for exclusion: (1) non-RCTs; (2) age &#x02264;17&#x000a0;years, diagnosis of stroke, brain tumors, and non-traumatic brain injuries; (3) crossover studies; (4) did not address any primary or secondary outcomes as mentioned above; and (5) for those studies that did not describe the randomization methods, we attempted to contact the original authors. If the original authors did not provide a response or the randomization method proved inadequate, the articles were excluded.</p></sec><sec id="Sec6"><title>Methodological quality evaluation</title><p>The methodological quality assessment table was based on the Cochrane Reviewers&#x02019; Handbook [<xref ref-type="bibr" rid="CR9">9</xref>] and the modified Jadad scale [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR11">11</xref>]. Data synthesis was conducted by R (R package version 3.7-0.) [<xref ref-type="bibr" rid="CR12">12</xref>]. We followed the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) statement to report the research protocol, outcome, and relevant items in this systematic review [<xref ref-type="bibr" rid="CR13">13</xref>].</p></sec></sec><sec id="Sec7"><title>Limitations of the study</title><p>Though there are many published literatures regarding the use of mannitol in severe traumatic brain injury patients, few of them have met the high quality standards of evidence-based medicine. There is insufficient reliable evidence to make suggestions on the administration of mannitol and many unanswered questions on the optimal use of mannitol in severe traumatic brain injury patients.</p></sec></sec><sec id="Sec8" sec-type="results"><title>Results and discussion</title><sec id="Sec9"><title>Study identification and selection</title><p>There were in total 176 potentially relevant titles, abstracts, and articles that have been screened. Initial screening resulted in 42 candidate studies [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR14">14</xref>&#x02013;<xref ref-type="bibr" rid="CR52">52</xref>]. Figure&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref> shows the details of the selection process and the reasons for exclusion. There were four trails that met all inclusion criteria and were included in the final meta-analysis. The characteristics of these included trials are listed in Tables&#x000a0;<xref rid="Tab2" ref-type="table">2</xref> and <xref rid="Tab3" ref-type="table">3</xref>.<fig id="Fig1"><label>Fig. 1</label><caption><p>Literature searching and selection</p></caption><graphic xlink:href="41038_2015_6_Fig1_HTML" id="MO1"/></fig><table-wrap id="Tab2"><label>Table 2</label><caption><p>Methodological characteristics of studies</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Author</th><th>Number of patients</th><th>Randomization</th><th>Concealment</th><th>Blinded</th><th>Withdraw</th><th>Single or multicenter</th><th>Balance of two groups</th><th>Total modified Jadad score</th></tr></thead><tbody><tr><td>Vialet et al. [<xref ref-type="bibr" rid="CR49">49</xref>]</td><td>20</td><td>Randomization table</td><td>Envelopes concealment</td><td>Single Blinded</td><td>0</td><td>Single center</td><td>Yes</td><td>7/7</td></tr><tr><td>Harutjunyan et al. [<xref ref-type="bibr" rid="CR50">50</xref>]</td><td>32</td><td>Computer randomly</td><td>Not reported</td><td>Not reported</td><td>0</td><td>Single center</td><td>Yes</td><td>3/7</td></tr><tr><td>Francony et al. [<xref ref-type="bibr" rid="CR51">51</xref>]</td><td>17</td><td>Randomization table</td><td>Envelopes concealment</td><td>Single blinded</td><td>0</td><td>Multi-center</td><td>Yes</td><td>7/7</td></tr><tr><td>Cottenceau et al. [<xref ref-type="bibr" rid="CR52">52</xref>]</td><td>56</td><td>Based on blocks of four</td><td>Envelopes concealment</td><td>Double blinded</td><td>0</td><td>Single center</td><td>Yes</td><td>7/7</td></tr></tbody></table></table-wrap><table-wrap id="Tab3"><label>Table 3</label><caption><p>The definition of secondary outcomes and surrogated endpoints of included trials</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Author</th><th>Patients</th><th>Interventions</th><th>Outcomes</th><th>Definition of surrogated endpoints</th></tr></thead><tbody><tr><td>Vialet et al. [<xref ref-type="bibr" rid="CR49">49</xref>]</td><td>Severe head injury (GCS &#x0003c;8); follow up to 3&#x000a0;months</td><td>The mannitol group receives 20&#x000a0;% mannitol solution. The hypertonic saline group received 7.5&#x000a0;% hypertonic saline. The infused volume was the same for the both solutions: 2&#x000a0;mL/kg body weight in 20&#x000a0;min</td><td>Death and neurological disability reported</td><td>HS caused a greater decrease in ICP than mannitol</td></tr><tr><td>Harutjunyan et al. [<xref ref-type="bibr" rid="CR50">50</xref>]</td><td>Severe neuronal damage (GCS &#x0003c;8).</td><td>Seventeen patients received 7.2&#x000a0;% NaCl/HES 200/0.5 and 15 received mannitol</td><td>Death reported</td><td>HES caused a greater decrease in ICP than mannitol (57 vs. 48&#x000a0;%; <italic>p</italic> &#x0003c;0.01)</td></tr><tr><td>Francony et al. [<xref ref-type="bibr" rid="CR51">51</xref>]</td><td>Severe brain injury (trauma, stroke); they were aged &#x0003e;18&#x000a0;years and had sustained elevated ICP of &#x0003e;20&#x000a0;mmHg for &#x0003e;10&#x000a0;min. Follow up to 3&#x000a0;months</td><td>The mannitol group received 231&#x000a0;mL of 20&#x000a0;% mannitol. The hypertonic saline group received 100&#x000a0;mL of 7.45&#x000a0;% hypertonic saline. Both to be administrated via the central venous catheter in 20&#x000a0;min</td><td>ICP, CPP, MAP reported</td><td>ICP decreasing did not differ between the two groups. Mannitol if effective than HS in CPP</td></tr><tr><td>Cottenceau et al. [<xref ref-type="bibr" rid="CR52">52</xref>]</td><td>Severe head injury (GCS &#x0003c;8); follow up to 6&#x000a0;months</td><td>The mannitol group received 4&#x000a0;mL/Kg of 20&#x000a0;% mannitol. The hypertonic saline group received 2&#x000a0;mL/Kg of 7.5&#x000a0;% hypertonic saline. Both be administrated in 20&#x000a0;min</td><td>Neurological outcome reported</td><td>Neurological outcome and ICP decreasing did not differ between the groups</td></tr></tbody></table></table-wrap></p></sec><sec id="Sec10"><title>Major outcome: mortality</title><p>Amongst all the enrolled studies, Vialet et al. [<xref ref-type="bibr" rid="CR49">49</xref>] and Harutjunyan et al. [<xref ref-type="bibr" rid="CR50">50</xref>] have provided the primary outcome (mortality) (Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref>, Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>). There is no heterogeneity between two studies (<italic>I</italic><sup>2</sup>&#x02009;=&#x02009;0&#x000a0;%), and a fixed model was used for the meta-analysis (<italic>n</italic>&#x02009;=&#x02009;53), pooled result indicated that the mortality was similar in mannitol intervention and control treatment, OR&#x02009;=&#x02009;0.80, 95&#x000a0;% CI [0, 27, 2.37], <italic>P</italic>&#x02009;=&#x02009;0.38.<table-wrap id="Tab4"><label>Table 4</label><caption><p>Mortality of included studies</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Studies</th><th>Mannitol group</th><th>Control group</th><th>
<italic>P</italic> value</th></tr></thead><tbody><tr><td>Vialet et al. [<xref ref-type="bibr" rid="CR49">49</xref>]</td><td>5/10 (50&#x000a0;%)</td><td>4/10 (40&#x000a0;%)</td><td>
<italic>P</italic> &#x0003e;0.05</td></tr><tr><td>Harutjunyan et al. [<xref ref-type="bibr" rid="CR50">50</xref>]</td><td>7/17 (41.2&#x000a0;%)</td><td>9/16 (56.2&#x000a0;%)</td><td>
<italic>P</italic> &#x0003e;0.05</td></tr></tbody></table></table-wrap><fig id="Fig2"><label>Fig. 2</label><caption><p>Comparison 1: mannitol versus hypertonic saline. Outcome 1 mortality</p></caption><graphic xlink:href="41038_2015_6_Fig2_HTML" id="MO2"/></fig></p></sec><sec id="Sec11"><title>Secondary outcomes</title><p>In terms of the report of the secondary outcomes and surrogate endpoints, four RCTs were not uniformed and the data synthesis was not available. Hence, we have conducted a qualitative analysis afterward. There was no difference between two groups in neurological outcome (Glasgow outcome scale (GOS) 5/10 vs. 6/10; <italic>P</italic> &#x0003e;0.05) and days on ICU (23.3&#x02009;&#x000b1;&#x02009;14.8 vs. 22.8&#x02009;&#x000b1;&#x02009;15.5; <italic>P</italic> &#x0003e;0.05). No trial reported ventilator day.</p></sec><sec id="Sec12"><title>Surrogated endpoints</title><sec id="Sec13"><title>ICP</title><p>Mannitol therapy may have a detrimental effect on decrease ICP when compared to hypertonic saline therapy. Vialet et al. [<xref ref-type="bibr" rid="CR49">49</xref>] compared 20&#x000a0;% mannitol group with 7.5&#x000a0;% HS group. The result suggested that the mean number (13.3&#x02009;&#x000b1;&#x02009;14.6 vs. 6.9&#x02009;&#x000b1;&#x02009;5.6 episodes) of intracranial hypertension episodes (ICP &#x0003e;25&#x000a0;mmHg) per day and the daily duration (131&#x02009;&#x000b1;&#x02009;123 vs. 67&#x02009;&#x000b1;&#x02009;85&#x000a0;min) of intracranial hypertension episodes were significantly higher in the mannitol group (<italic>P</italic> &#x0003c;0.01) than those in the HS group [<xref ref-type="bibr" rid="CR49">49</xref>]. The rate of clinical failure was also significantly higher in the mannitol group (7 of 10 vs. 1 of 10 patients; <italic>P</italic> &#x0003c;0.01) than that in the HS group [<xref ref-type="bibr" rid="CR49">49</xref>]. Harutjunyan et al. [<xref ref-type="bibr" rid="CR50">50</xref>] compared 15&#x000a0;% mannitol to 7.2&#x000a0;% hypertonic saline hydroxyethyl starch 200/0.5 (7.2&#x000a0;% NaCl/HES 200/0.5). NaCl/HES 200/0.5 (7.2&#x000a0;%) caused a greater decrease in the ICP than mannitol did (57 vs. 48&#x000a0;%; <italic>P</italic> &#x0003c;0.01) [<xref ref-type="bibr" rid="CR50">50</xref>]. Both groups decreased the ICP to below 15&#x000a0;mmHg; but the mean time was significantly longer in the mannitol group (8.7 vs. 6&#x000a0;min; <italic>P</italic> &#x0003c;0.01) than that in the HS group. Francony et al. [<xref ref-type="bibr" rid="CR51">51</xref>] and Cottenceau et al. [<xref ref-type="bibr" rid="CR52">52</xref>] have shown that the spectrum of the ICP decrease was significantly larger in the HS group than in the mannitol group, and the spectrum was about 10&#x000a0;% over the entire stage. The changes of ICP across the four studies are summarized in Table&#x000a0;<xref rid="Tab5" ref-type="table">5</xref>.<table-wrap id="Tab5"><label>Table 5</label><caption><p>ICP of included studies</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2"/><th rowspan="2"/><th colspan="3">Measurement of surrogate index</th><th colspan="2">Measurement of surrogate index</th></tr><tr><th colspan="3">Number of episodes per day</th><th colspan="2">Total duration of episodes, min/day</th></tr></thead><tbody><tr><td rowspan="2">Vialet et al. [<xref ref-type="bibr" rid="CR49">49</xref>]</td><td>Intervention: 20&#x000a0;%&#x000a0;M 2&#x000a0;mL/Kg</td><td>13.3&#x02009;&#x000b1;&#x02009;14.2<sup>**</sup>
</td><td/><td/><td/><td>95&#x02009;&#x000b1;&#x02009;92<sup>**</sup>
</td></tr><tr><td>Control: 7.5&#x000a0;% HSS 2&#x000a0;mL/Kg</td><td>6.8&#x02009;&#x000b1;&#x02009;5.5<sup>**</sup>
</td><td/><td/><td/><td>62&#x02009;&#x000b1;&#x02009;81<sup>**</sup>
</td></tr><tr><td/><td/><td>T0</td><td>T30</td><td>T60</td><td>T90</td><td>T120</td></tr><tr><td rowspan="2">Harutjunyan et al. [<xref ref-type="bibr" rid="CR50">50</xref>]</td><td>Intervention: 15&#x000a0;%&#x000a0;M 1.4&#x000a0;mL/Kg</td><td>23 [19&#x02013;30]</td><td>12 [6&#x02013;19]<sup>*</sup>
</td><td>14 [7&#x02013;20]<sup>*,**</sup>
</td><td/><td/></tr><tr><td>Control: 7.2&#x000a0;% NaCl/HES 1.8&#x000a0;mL/Kg</td><td>22 [19&#x02013;31]</td><td>10 [6&#x02013;14]<sup>*</sup>
</td><td>11 [5&#x02013;18]</td><td/><td/></tr><tr><td rowspan="2">Cottenceau et al. [<xref ref-type="bibr" rid="CR52">52</xref>]</td><td>Intervention: 20&#x000a0;%&#x000a0;M 4&#x000a0;mL/Kg</td><td>16.3&#x02009;&#x000b1;&#x02009;9.3</td><td>10.5&#x02009;&#x000b1;&#x02009;6.8<sup>*</sup>
</td><td/><td/><td>13.6&#x02009;&#x000b1;&#x02009;7.5<sup>*</sup>
</td></tr><tr><td>Control: 7.5&#x000a0;% HSS 2&#x000a0;mL/Kg</td><td>17.9&#x02009;&#x000b1;&#x02009;9.9</td><td>13.9&#x02009;&#x000b1;&#x02009;7.8<sup>*</sup>
</td><td/><td/><td>13.9&#x02009;&#x000b1;&#x02009;7.8<sup>*</sup>
</td></tr><tr><td/><td/><td>&#x00394;%</td><td>&#x00394;%</td><td>&#x00394;%</td><td>&#x00394;%</td><td>&#x00394;%</td></tr><tr><td rowspan="2">Francony et al. [<xref ref-type="bibr" rid="CR51">51</xref>]</td><td>Intervention: 20&#x000a0;%&#x000a0;M 231&#x000a0;mL</td><td>31&#x02009;&#x000b1;&#x02009;6</td><td>&#x02212;41&#x02009;&#x000b1;&#x02009;23<sup>*</sup>
</td><td>&#x02212;45&#x02009;&#x000b1;&#x02009;19<sup>*</sup>
</td><td>&#x02212;35&#x02009;&#x000b1;&#x02009;12<sup>*</sup>
</td><td>&#x02212;32&#x02009;&#x000b1;&#x02009;12<sup>*</sup>
</td></tr><tr><td>Control: 7.45&#x000a0;% HSS 100&#x000a0;mL</td><td>27&#x02009;&#x000b1;&#x02009;3</td><td>&#x02212;37&#x02009;&#x000b1;&#x02009;18<sup>*</sup>
</td><td>&#x02212;35&#x02009;&#x000b1;&#x02009;14<sup>*</sup>
</td><td>&#x02212;31&#x02009;&#x000b1;&#x02009;15<sup>*</sup>
</td><td>&#x02212;23&#x02009;&#x000b1;&#x02009;10<sup>*</sup>
</td></tr></tbody></table><table-wrap-foot><p>*<italic>P</italic> &#x0003c;0.05 vs. T0; **<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05 vs. mannitol</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec14"><title>CPP</title><p>Mannitol therapy may have a small detrimental effect in increasing CCP when compared to hypertonic saline therapy. Mannitol therapy may only have a beneficial effect in improving the blood supply of local brain tissue. Vialet et al. [<xref ref-type="bibr" rid="CR49">49</xref>] has indicated that there was no significant difference in the mean number (3.1&#x02009;&#x000b1;&#x02009;3.6 vs. 4.0&#x02009;&#x000b1;&#x02009;4.6 episodes) of cerebral perfusion hypotension episodes (CPP &#x0003c;70&#x000a0;mmHg) per day and the daily duration (62&#x02009;&#x000b1;&#x02009;107 vs. 52&#x02009;&#x000b1;&#x02009;83&#x000a0;min) of cerebral perfusion hypotension episodes between the two groups (<italic>P</italic> &#x0003e;0.05) [<xref ref-type="bibr" rid="CR49">49</xref>]. Harutjunyan et al. [<xref ref-type="bibr" rid="CR50">50</xref>] has shown that the CPP had significantly sharp increase in both groups after the start of the infusion (<italic>P</italic> &#x0003c;0.0001), and the HS group was significantly higher than the mannitol group at 30&#x000a0;min after the beginning of the infusion (<italic>P</italic> &#x0003c;0.05) [<xref ref-type="bibr" rid="CR50">50</xref>]. The maximum increase occurred at 30&#x000a0;min after the beginning of the infusion in both groups, and the HS group increased more than the mannitol group did (27 vs. 18&#x000a0;%; <italic>P</italic> &#x0003c;0.05) [<xref ref-type="bibr" rid="CR50">50</xref>]. Francony et al. [<xref ref-type="bibr" rid="CR51">51</xref>] suggested that mannitol could only effectively improve the CPP and the blood supply of the local brain tissue [<xref ref-type="bibr" rid="CR51">51</xref>]. Cottenceau et al. [<xref ref-type="bibr" rid="CR52">52</xref>] suggested that the maximum of CPP increase occurred at 30&#x000a0;min after the beginning of the infusion in both groups, but there was no significantly difference between the 20&#x000a0;% mannitol and the 7.5&#x000a0;% HS group [<xref ref-type="bibr" rid="CR52">52</xref>]. The changes of CCP across the four studies are summarized in Table&#x000a0;<xref rid="Tab6" ref-type="table">6</xref>.<table-wrap id="Tab6"><label>Table 6</label><caption><p>CPP of included studies</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2"/><th rowspan="2"/><th colspan="3">Measurement of surrogate index</th><th colspan="2">Measurement of surrogate index</th></tr><tr><th colspan="3">Number of episodes per day</th><th colspan="2">Total duration of episodes, min/day</th></tr></thead><tbody><tr><td rowspan="2">Vialet et al. [<xref ref-type="bibr" rid="CR49">49</xref>]</td><td>Intervention: 20&#x000a0;%&#x000a0;M 2&#x000a0;mL/Kg</td><td>3.1&#x02009;&#x000b1;&#x02009;3.6<sup>**</sup>
</td><td/><td/><td>62&#x02009;&#x000b1;&#x02009;107<sup>**</sup>
</td><td/></tr><tr><td>Control: 7.5&#x000a0;% HSS 2&#x000a0;mL/Kg</td><td>4.0&#x02009;&#x000b1;&#x02009;4.6<sup>**</sup>
</td><td/><td/><td>58&#x02009;&#x000b1;&#x02009;83<sup>**</sup>
</td><td/></tr><tr><td/><td/><td>T0</td><td>T30</td><td>T60</td><td>T90</td><td>T120</td></tr><tr><td rowspan="2">Harutjunyan et al. [<xref ref-type="bibr" rid="CR50">50</xref>]</td><td>Intervention: 15&#x000a0;%&#x000a0;M 1.4&#x000a0;mL/Kg</td><td>61 [47&#x02013;71]</td><td>72 [60&#x02013;93]<sup>*</sup>
</td><td>73 [58&#x02013;88]<sup>*,**</sup>
</td><td/><td/></tr><tr><td>Control: 7.2&#x000a0;% NaCl/HES 1.8&#x000a0;mL/Kg</td><td>60 [39&#x02013;78]</td><td>75 [62&#x02013;86]<sup>*,**</sup>
</td><td>69 [56&#x02013;89]<sup>*</sup>
</td><td/><td/></tr><tr><td rowspan="2">Cottenceau et al. [<xref ref-type="bibr" rid="CR52">52</xref>]</td><td>Intervention: 20&#x000a0;%&#x000a0;M 4&#x000a0;mL/Kg</td><td>72.1&#x02009;&#x000b1;&#x02009;12.8</td><td>76.9&#x02009;&#x000b1;&#x02009;17.4<sup>8</sup>
</td><td/><td/><td>74.7&#x02009;&#x000b1;&#x02009;13.3<sup>*</sup>
</td></tr><tr><td>Control: 7.5&#x000a0;% HSS 2&#x000a0;mL/Kg</td><td>72.8&#x02009;&#x000b1;&#x02009;15.1</td><td>79.3&#x02009;&#x000b1;&#x02009;11.6<sup>*</sup>
</td><td/><td/><td>74.3&#x02009;&#x000b1;&#x02009;13.1<sup>*</sup>
</td></tr><tr><td/><td/><td>&#x00394;%</td><td>&#x00394;%</td><td>&#x00394;%</td><td>&#x00394;%</td><td>&#x00394;%</td></tr><tr><td rowspan="2">Francony et al. [<xref ref-type="bibr" rid="CR51">51</xref>]</td><td>Intervention: 20&#x000a0;%&#x000a0;M 231&#x000a0;mL</td><td>75&#x02009;&#x000b1;&#x02009;15</td><td>+21&#x02009;&#x000b1;&#x02009;23<sup>*</sup>
</td><td>+22&#x02009;&#x000b1;&#x02009;21<sup>*</sup>
</td><td>+14&#x02009;&#x000b1;&#x02009;15<sup>*</sup>
</td><td>+17&#x02009;&#x000b1;&#x02009;14<sup>*</sup>
</td></tr><tr><td>Control: 7.45&#x000a0;% HSS 100&#x000a0;mL</td><td>81&#x02009;&#x000b1;&#x02009;12</td><td>+21&#x02009;&#x000b1;&#x02009;23<sup>*</sup>
</td><td>+9&#x02009;&#x000b1;&#x02009;10<sup>*</sup>
</td><td>+8&#x02009;&#x000b1;&#x02009;11<sup>*</sup>
</td><td>+7&#x02009;&#x000b1;&#x02009;6<sup>*</sup>
</td></tr></tbody></table><table-wrap-foot><p>*<italic>P</italic> &#x0003c;0.05 vs. T0; **<italic>P</italic> &#x0003c;0.05 vs. mannitol</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec15"><title>MAP</title><p>Mannitol therapy may have no beneficial effect in increasing MAP when compared to hypertonic saline therapy. Harutjunyan et al. [<xref ref-type="bibr" rid="CR50">50</xref>] shown that MAP had a significantly sharp increase in 15&#x000a0;% mannitol and 7.2&#x000a0;% NaCl/HES 200/0.5 after the beginning of the infusion (<italic>P</italic> &#x0003c;0.05). There was no significant difference in the increase of MAP between two groups (5.8 vs. 7.6&#x000a0;%), but the maximum increase occurred significantly shorter in the mannitol group than in the HS group (10 vs. 30&#x000a0;min) [<xref ref-type="bibr" rid="CR50">50</xref>]. Francony et al. [<xref ref-type="bibr" rid="CR51">51</xref>] and Cottenceau et al. [<xref ref-type="bibr" rid="CR52">52</xref>] have shown in their research that there was no significant difference in MAP between the 20&#x000a0;% mannitol and the 7.5&#x000a0;% HS. The changes of MAP across the four studies are summarized in Table&#x000a0;<xref rid="Tab7" ref-type="table">7</xref>.<table-wrap id="Tab7"><label>Table 7</label><caption><p>MAP of included studies</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th/><th>T0</th><th>T30</th><th>T60</th><th>T90</th><th>T120</th></tr></thead><tbody><tr><td rowspan="2">Harutjunyan et al. [<xref ref-type="bibr" rid="CR50">50</xref>]</td><td>Intervention: 15&#x000a0;%&#x000a0;M 1.4&#x000a0;mL/Kg</td><td>84 [68&#x02013;92]</td><td>81 [69&#x02013;106]</td><td>82 [68&#x02013;108]</td><td/><td/></tr><tr><td>Control: 7.2&#x000a0;% NaCl/HES 1.8&#x000a0;mL/Kg</td><td>84 [64&#x02013;98]</td><td>85 [74&#x02013;100]<sup>*,**</sup>
</td><td>84 [63&#x02013;94]<sup>*</sup>
</td><td/><td/></tr><tr><td rowspan="2">Cottenceau et al. [<xref ref-type="bibr" rid="CR52">52</xref>]</td><td>Intervention: 20 %M 4&#x000a0;mL/Kg</td><td>87.6&#x02009;&#x000b1;&#x02009;12.2</td><td>87.4&#x02009;&#x000b1;&#x02009;11.6</td><td/><td/><td>87.9&#x02009;&#x000b1;&#x02009;10.9</td></tr><tr><td>Control: 7.5&#x000a0;% HSS 2&#x000a0;mL/Kg</td><td>90.6&#x02009;&#x000b1;&#x02009;12.6</td><td>91.2&#x02009;&#x000b1;&#x02009;10</td><td/><td/><td>87.2&#x02009;&#x000b1;&#x02009;10.5</td></tr><tr><td/><td/><td>&#x00394;%</td><td>&#x00394;%</td><td>&#x00394;%</td><td>&#x00394;%</td><td>&#x00394;%</td></tr><tr><td rowspan="2">Francony et al. [<xref ref-type="bibr" rid="CR51">51</xref>]</td><td>Intervention: 20&#x000a0;%&#x000a0;M 231&#x000a0;mL</td><td>106&#x02009;&#x000b1;&#x02009;16</td><td>+2&#x02009;&#x000b1;&#x02009;9</td><td>+1&#x02009;&#x000b1;&#x02009;10</td><td>0&#x02009;&#x000b1;&#x02009;10<sup>*</sup>
</td><td>+2&#x02009;&#x000b1;&#x02009;7</td></tr><tr><td>Control: 7.45 %Hss 100&#x000a0;mL</td><td>108&#x02009;&#x000b1;&#x02009;13</td><td>&#x02212;5&#x02009;&#x000b1;&#x02009;7</td><td>&#x02212;2&#x02009;&#x000b1;&#x02009;7</td><td>&#x02212;3&#x02009;&#x000b1;&#x02009;7<sup>*</sup>
</td><td>&#x02212;1&#x02009;&#x000b1;&#x02009;5</td></tr></tbody></table><table-wrap-foot><p>*<italic>P</italic> &#x0003c;0.05 vs. T0; **<italic>P</italic> &#x0003c;0.05 vs. mannitol</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec16"><title>Plasma osmolality, urine, and serum sodium</title><p>Mannitol therapy may have no difference in elevating the plasma osmolality and serum sodium when compared to hypertonic saline therapy. Mannitol therapy may have a small beneficial effect in increasing the urine output. But the single trial was too small for reliable conclusion. Vialet et al. [<xref ref-type="bibr" rid="CR49">49</xref>] suggested that the plasma osmolality and serum sodium elevated significantly in both the 20&#x000a0;% mannitol group and the 7.5&#x000a0;% HS group after the beginning of the infusion (<italic>P</italic> &#x0003c;0.05), but there was no significant difference between the two groups. Harutjunyan et al. [<xref ref-type="bibr" rid="CR50">50</xref>] showed the serum sodium increased in both the 15&#x000a0;% mannitol and the 7.2&#x000a0;% NaCl/HES 200/0.5 (<italic>P</italic> &#x0003c;0.05), although there was no significant difference between the two groups. Francony et al. suggested that mannitol caused a significantly greater increase in urine output (<italic>P</italic> 0.05) than HS [<xref ref-type="bibr" rid="CR51">51</xref>]. Cottenceau et al. suggested that the HS caused a significantly greater increase of serum sodium (<italic>P</italic>&#x02009;=&#x02009;0.0000), although mannitol caused a significantly decrease of it (<italic>P</italic>&#x02009;=&#x02009;0.0000) [<xref ref-type="bibr" rid="CR52">52</xref>]. The changes of plasma osmolality and sodium across the four studies are summarized in Table&#x000a0;<xref rid="Tab8" ref-type="table">8</xref>.<table-wrap id="Tab8"><label>Table 8</label><caption><p>Plasma osmolality and serum sodium of included studies</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th colspan="2">Measurement of surrogate index</th><th>Intervention</th><th>Control</th></tr></thead><tbody><tr><td>Vialet et al. [<xref ref-type="bibr" rid="CR49">49</xref>]</td><td>Serum sodium (&#x00394;%)</td><td/><td>+1.3&#x02009;&#x000b1;&#x02009;10.1<sup>*</sup>
</td><td>+4.7&#x02009;&#x000b1;&#x02009;8.2<sup>*</sup>
</td></tr><tr><td rowspan="2">Francony et al. [<xref ref-type="bibr" rid="CR51">51</xref>]</td><td>Serum sodium (&#x00394;%)</td><td/><td>&#x02212;1.7&#x02009;&#x000b1;&#x02009;3.2<sup>**</sup>
</td><td>+2.1&#x02009;&#x000b1;&#x02009;1.4<sup>**</sup>
</td></tr><tr><td>Urine output (mL/h)</td><td/><td>306&#x02009;&#x000b1;&#x02009;174<sup>**</sup>
</td><td>114&#x02009;&#x000b1;&#x02009;72<sup>**</sup>
</td></tr><tr><td rowspan="4">Harutjunyan et al. [<xref ref-type="bibr" rid="CR50">50</xref>]</td><td rowspan="2">Serum sodium</td><td>T0</td><td/><td>143 (136&#x02013;148)</td></tr><tr><td>T30</td><td/><td>148 (144&#x02013;153)<sup>*</sup>
</td></tr><tr><td>Plasma</td><td>T0</td><td>286 (270&#x02013;315)<sup>*</sup>
</td><td>284 (273&#x02013;300)<sup>*</sup>
</td></tr><tr><td>Osmolality</td><td>T30</td><td>295 (278&#x02013;327)<sup>*</sup>
</td><td>300 (284&#x02013;319)<sup>*</sup>
</td></tr><tr><td rowspan="2">Cottenceau et al. [<xref ref-type="bibr" rid="CR52">52</xref>]</td><td rowspan="2">Serum sodium</td><td>T0</td><td>141.3&#x02009;&#x000b1;&#x02009;5.1</td><td>144.2&#x02009;&#x000b1;&#x02009;5.1</td></tr><tr><td>T30</td><td>139.1&#x02009;&#x000b1;&#x02009;4.1<sup>*,**</sup>
</td><td>148.3&#x02009;&#x000b1;&#x02009;5.2<sup>*,**</sup>
</td></tr></tbody></table><table-wrap-foot><p>*<italic>P</italic> &#x0003c;0.05 vs. T0; **<italic>P</italic> &#x0003c;0.05 vs. mannitol</p></table-wrap-foot></table-wrap></p></sec></sec></sec><sec id="Sec17" sec-type="conclusion"><title>Conclusions</title><p>Published literatures regarding the use of mannitol in severe traumatic brain injury patients have rarely met the high quality standards of evidence-based medicine. This systematic review has revealed that the mannitol therapy cannot reduce death risk for TBI patients suffering from raised ICP.</p><p>Four RCTs retrieved by this study which have found reduced intracranial pressure (ICP): two RCTs suggested that hypertonic saline was superior to mannitol, and the time of maximized effect was earlier than that of mannitol; whilst the other two RCTs have proposed mannitol was equally on the impact of ICP comparing with hypertonic saline. In the elevation of CPP and MAP, one RCT found that hypertonic saline was superior to mannitol, whilst the other three RCTs considered no significant difference between the two agents. One RCT showed that mannitol might have a beneficial effect on cerebral hemodynamic when compare to hypertonic saline. However, some domestic studies have shown that the 23.4&#x000a0;% HS have faster and longer effect than the 20&#x000a0;% mannitol did in the treatment of raised ICP of severe brain injury [<xref ref-type="bibr" rid="CR53">53</xref>&#x02013;<xref ref-type="bibr" rid="CR56">56</xref>]. Thus, the points of those researchers on this issue are varied and contradicted with each other.</p><p>Currently, mannitol is widely used as a part of conventional therapy of the TBI patients who suffer from intracranial pressure hypertension. Based on the most credible evidence from this study, mannitol therapy cannot reduce the mortality risk in this type of patients. Well-designed randomized controlled trials are urgently needed to demonstrate the efficacy of mannitol to acute severe traumatic brain injury.</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>CI</term><def><p>confidence interval</p></def></def-item><def-item><term>CPP</term><def><p>cerebral perfusion pressure</p></def></def-item><def-item><term>GCS</term><def><p>Glasgow coma score</p></def></def-item><def-item><term>HES</term><def><p>hydroxyethyl starch</p></def></def-item><def-item><term>HS</term><def><p>hypertonic saline</p></def></def-item><def-item><term>ICP</term><def><p>intracranial pressure</p></def></def-item><def-item><term>ICU</term><def><p>intensive unit care</p></def></def-item><def-item><term>MAP</term><def><p>mean arterial pressure</p></def></def-item><def-item><term>OR</term><def><p>odds ratio</p></def></def-item><def-item><term>PRISMA</term><def><p>Preferred Reporting Items for Systematic Reviews and Meta-Analyses</p></def></def-item><def-item><term>RCT</term><def><p>randomized controlled trial</p></def></def-item><def-item><term>TBI</term><def><p>traumatic brain injury</p></def></def-item></def-list></glossary><fn-group><fn><p>Kai Wang and Mingwei Sun contributed equally to this work.</p></fn><fn><p><bold>Competing interests</bold></p><p>The authors declare that they have no competing interests.</p></fn><fn><p><bold>Authors&#x02019; contributions</bold></p><p>Study design and conception of this manuscript were performed by KW, M-WS, HJ, and JZ. Literature retrieving and study selection were performed by KW and M-WS. KW, HJ, and X-PC performed quality evaluation of the study. Mathematical modeling and meta-analysis are conducted by KW, JZ, and HJ. Results analysis and interpretation are done by M-WS, HJ, X-PC, and JZ. The manuscript was drafted by KW, M-WS, and HJ. KW, and M-WS contributed equally to this work. All authors read and approved the final manuscript.</p></fn></fn-group><ack><title>Acknowledgements</title><p>The authors appreciate Mr. Andrew He of University of Waikato for his generous help on the manuscript writing and proofreading.</p><sec id="FPar1"><title>Funding</title><p>This work was supported by grants from Sichuan Provincial Department of Science and Technology (No. 2012SZ0181, SZ20120209) and grants from Chengdu Municipality Department of Science and Technology (11PPYB099SF-289 AND 12PPYB181SF-002). Funders play no role on the study design, conduct, and manuscript writing.</p></sec></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Archer</surname><given-names>DP</given-names></name><name><surname>Freymond</surname><given-names>D</given-names></name><name><surname>Ravussin</surname><given-names>P</given-names></name></person-group><article-title>Use of mannitol in neuro anesthesia and neuro intensive care</article-title><source>Ann Fr Anesth Reanim.</source><year>1995</year><volume>14</volume><fpage>77</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1016/S0750-7658(05)80154-6</pub-id><pub-id pub-id-type="pmid">7677291</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oken</surname><given-names>DE</given-names></name></person-group><article-title>Renal extrarenal consideration in high-dose mannitol therapy</article-title><source>Ren Fail.</source><year>1994</year><volume>16</volume><fpage>147</fpage><lpage>59</lpage><pub-id pub-id-type="doi">10.3109/08860229409044856</pub-id><pub-id pub-id-type="pmid">8184141</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaufmann</surname><given-names>AM</given-names></name><name><surname>Cardoso</surname><given-names>ER</given-names></name></person-group><article-title>Aggravation of vasogenic cerebral edema by multiple-dose mannitol</article-title><source>Neurosurg.</source><year>1992</year><volume>77</volume><fpage>584</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.3171/jns.1992.77.4.0584</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>WakaiA</surname><given-names>MCA</given-names></name><name><surname>Roberts</surname><given-names>I</given-names></name></person-group><article-title>Mannitol for acute traumatic brain injury</article-title><source>Cochrane Database SystRev.</source><year>2013</year><volume>8</volume><fpage>CD001049</fpage></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>W-Q</given-names></name><name><surname>Zeng</surname><given-names>H-K</given-names></name><name><surname>Chen</surname><given-names>C-B</given-names></name></person-group><article-title>Comparison between HS with mannitol in the treatment of intracranial hypertension: a systematic review</article-title><source>J Evidence Based Med.</source><year>2008</year><volume>10</volume><fpage>279</fpage><lpage>83</lpage></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>M</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Jiang</surname><given-names>H</given-names></name><name><surname>Peng</surname><given-names>J</given-names></name><name><surname>Cai</surname><given-names>B</given-names></name><name><surname>Hu</surname><given-names>W</given-names></name><etal/></person-group><article-title>Hypertonic solution dose not decrease mortality from traumatic hemorrhagic shock: a systematic review and meta-analysis based on randomized control trials</article-title><source>Chin J Emerg Med.</source><year>2014</year><volume>11</volume><fpage>195</fpage><lpage>8</lpage></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liang</surname><given-names>J-T</given-names></name><name><surname>Peng</surname><given-names>Y-Q</given-names></name><name><surname>Ke</surname><given-names>B-F</given-names></name></person-group><article-title>The clinical study of repeated use of mannitol to treat intracranial hypertension of the patients with severe craniocerebral injury</article-title><source>Int J Clin Exp Med.</source><year>2008</year><volume>7</volume><fpage>23</fpage><lpage>4</lpage></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>Z-P</given-names></name><name><surname>Chen</surname><given-names>C-Y</given-names></name></person-group><article-title>Clinical analysis of alternate use of hypertonic saline and mannitol in treatment of postoperative intracranial hypertension in severe traumatic brain injury</article-title><source>Chin Modern Med.</source><year>2013</year><volume>20</volume><fpage>82</fpage><lpage>3</lpage></element-citation></ref><ref id="CR9"><label>9.</label><mixed-citation publication-type="other">Higgins JPT. Cochrane handbook for systematic reviews of interventions version 5.0.1. The Cochrane Collaboration. 2008. <ext-link ext-link-type="uri" xlink:href="http://www.cochrane-handbook.org/">http://www.Cochrane-handbook.org</ext-link>. Accessed 19 May 2015.</mixed-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jadad</surname><given-names>AR</given-names></name><name><surname>Moore</surname><given-names>RA</given-names></name><name><surname>Carroll</surname><given-names>D</given-names></name><name><surname>Jenkinson</surname><given-names>C</given-names></name><name><surname>Reynolds</surname><given-names>DJ</given-names></name><name><surname>Gavaghan</surname><given-names>DJ</given-names></name><etal/></person-group><article-title>Assessing the quality of reports of randomized clinical trials: is blinding necessary</article-title><source>Control Clin Trials.</source><year>1996</year><volume>17</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1016/0197-2456(95)00134-4</pub-id><pub-id pub-id-type="pmid">8721797</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Min</surname><given-names>G</given-names></name><name><surname>Liu</surname><given-names>F</given-names></name><name><surname>Zhai</surname><given-names>S</given-names></name><name><surname>Zhu</surname><given-names>JS</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>T</given-names></name></person-group><article-title>Salbutamol in preventing preterm labour: a systematic review</article-title><source>Chin J Evid Based Med.</source><year>2007</year><volume>7</volume><fpage>591</fpage><lpage>600</lpage></element-citation></ref><ref id="CR12"><label>12.</label><mixed-citation publication-type="other">Guido Schwarzer. 2014. Meta: meta-analysis with R. R package version 3.7-0. <ext-link ext-link-type="uri" xlink:href="http://cran.r-project.org/package=meta">http://CRAN.R-project.org/package=meta</ext-link>. Accessed 19 May 2015.</mixed-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moher</surname><given-names>D</given-names></name><name><surname>Liberati</surname><given-names>A</given-names></name><name><surname>Tetzlaff</surname><given-names>J</given-names></name><name><surname>Altman</surname><given-names>DG</given-names></name><collab>PRISMA Group</collab></person-group><article-title>Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement</article-title><source>PLoS Med.</source><year>2009</year><volume>6</volume><fpage>e1000097</fpage><pub-id pub-id-type="doi">10.1371/journal.pmed.1000097</pub-id><pub-id pub-id-type="pmid">19621072</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Xu</surname><given-names>P</given-names></name><name><surname>Gao</surname><given-names>R</given-names></name><etal/></person-group><article-title>The effect of 3&#x000a0;% hypertonic saline in intracranial pressure decreasing of patients with severe traumatic brain injury</article-title><source>Jiangsu Med J.</source><year>2008</year><volume>34</volume><fpage>520</fpage><lpage>1</lpage></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mao</surname><given-names>X</given-names></name><name><surname>Feng</surname><given-names>D</given-names></name><name><surname>Ye</surname><given-names>F</given-names></name></person-group><article-title>Comparison of mannitol with hypotonic saline in treatment of traumatic brain edema associated with intracranial hypertension</article-title><source>Jiangsu Med J.</source><year>2007</year><volume>33</volume><fpage>452</fpage><lpage>4</lpage></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schwarz</surname><given-names>S</given-names></name><name><surname>Schwab</surname><given-names>S</given-names></name><name><surname>Bertram</surname><given-names>M</given-names></name><name><surname>Aschoff</surname><given-names>A</given-names></name><name><surname>Hacke</surname><given-names>W</given-names></name></person-group><article-title>Effects of hypertonic saline hydroxyethyl starch solution and mannitol in patients with increased intracranial pressure after stroke</article-title><source>Stroke.</source><year>1998</year><volume>29</volume><fpage>1550</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1161/01.STR.29.8.1550</pub-id><pub-id pub-id-type="pmid">9707191</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ichai</surname><given-names>C</given-names></name><name><surname>Armando</surname><given-names>G</given-names></name><name><surname>Orban</surname><given-names>JC</given-names></name><name><surname>Berthier</surname><given-names>F</given-names></name><name><surname>Rami</surname><given-names>L</given-names></name><name><surname>Samat-Long</surname><given-names>C</given-names></name><etal/></person-group><article-title>Sodium lactate versus mannitol in the treatment of intracranial hypertensive episodes in severe traumatic brain-injured patients</article-title><source>Intensive Care Med.</source><year>2009</year><volume>35</volume><fpage>471</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1007/s00134-008-1283-5</pub-id><pub-id pub-id-type="pmid">18807008</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soustiel</surname><given-names>JF</given-names></name><name><surname>Mahamid</surname><given-names>E</given-names></name><name><surname>Chistyakov</surname><given-names>A</given-names></name><name><surname>Shik</surname><given-names>V</given-names></name><name><surname>Benenson</surname><given-names>R</given-names></name><name><surname>Zaaroor</surname><given-names>M</given-names></name></person-group><article-title>Comparison of moderate hyperventilation and mannitol for control of intracranial pressure control in patients with severe traumatic brain injury&#x02014;a study of cerebral blood flow and metabolism</article-title><source>Acta Neurochir (Wien).</source><year>2006</year><volume>148</volume><fpage>845</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1007/s00701-006-0792-7</pub-id><pub-id pub-id-type="pmid">16763735</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wakai</surname><given-names>A</given-names></name><name><surname>Roberts</surname><given-names>IG</given-names></name><name><surname>Schierhout</surname><given-names>G</given-names></name></person-group><article-title>Mannitol for acute traumatic brain injury</article-title><source>Cochrane Database Syst Rev</source><year>2007</year><volume>24</volume><issue>1</issue><fpage>CD001049</fpage><pub-id pub-id-type="pmid">17253453</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marshall</surname><given-names>LF</given-names></name><name><surname>SMith</surname><given-names>RW</given-names></name><name><surname>Rauscher</surname><given-names>LA</given-names></name></person-group><article-title>Mannitol dose requirements in brain-injured patients</article-title><source>J Neurosurg.</source><year>1978</year><volume>48</volume><fpage>584</fpage><lpage>9</lpage></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roberts</surname><given-names>IG</given-names></name><name><surname>Schierhout</surname><given-names>G</given-names></name><name><surname>Wakai</surname><given-names>A</given-names></name></person-group><article-title>Mannitol for acute traumatic brain injury</article-title><source>Cochrane Database Syst Rev.</source><year>2003</year><volume>2</volume><fpage>CD001049</fpage><pub-id pub-id-type="pmid">12804397</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>R</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name></person-group><article-title>Effects of 7.5 % hypertonic saline on brain edema after severe traumatic brain injury</article-title><source>J Med Sci Central South China</source><year>2012</year><volume>40</volume><fpage>487</fpage><lpage>9</lpage></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name></person-group><article-title>Systematic review of the safety and efficacy of hypertonic saline and mannitol treatment of intracranial hypertension</article-title><source>Chin Med Herald.</source><year>2011</year><volume>8</volume><fpage>11</fpage><lpage>3</lpage></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bin</surname><given-names>X</given-names></name><name><surname>Jian-guo</surname><given-names>LI</given-names></name><name><surname>Zhang</surname><given-names>C-J</given-names></name><etal/></person-group><article-title>Effects of hypertonic saline and treatment of acute intracranial hemorrhage: comparative study of 12 cases</article-title><source>Chin J Emergency Resuscitat Disaster Med.</source><year>2010</year><volume>5</volume><fpage>731</fpage><lpage>3</lpage></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lei</surname><given-names>M</given-names></name><name><surname>Guan</surname><given-names>Z-L</given-names></name><name><surname>Yang</surname><given-names>G-S</given-names></name></person-group><article-title>Hypertonic saline treatment of traumatic intracranial hypertension</article-title><source>Chin J Med Guide.</source><year>2010</year><volume>6</volume><fpage>982</fpage><lpage>3</lpage></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chai</surname><given-names>F</given-names></name><name><surname>Luo</surname><given-names>X</given-names></name><name><surname>Liang</surname><given-names>MA</given-names></name></person-group><article-title>Efficacy of using hypertonic saline and mannitol for cerebral edema</article-title><source>Chin J Mod Drug Appl.</source><year>2009</year><volume>3</volume><fpage>23</fpage><lpage>4</lpage></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>B</given-names></name><name><surname>Ke</surname><given-names>J</given-names></name></person-group><article-title>Comparative analysis of the treatment of using 3&#x000a0;% hypertonic saline, mannitol, glycerol and fructose for intracranial hypertension</article-title><source>Chin Manipul Rehabil Med.</source><year>2011</year><volume>4</volume><fpage>93</fpage></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zeng</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Sun</surname><given-names>C</given-names></name><etal/></person-group><article-title>Applied research of hypertonic saline in intracranial hypertension</article-title><source>Chin J Emerg Med.</source><year>2004</year><volume>13</volume><fpage>264</fpage><lpage>6</lpage></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>W</given-names></name></person-group><article-title>Study on efficiency of treatment of elevated intracranial pressure of severe head injury patients with 3&#x000a0;% hypertonic saline</article-title><source>West China Med J.</source><year>2009</year><volume>24</volume><fpage>1349</fpage><lpage>51</lpage></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sayre</surname><given-names>MR</given-names></name><name><surname>Daily</surname><given-names>SW</given-names></name><name><surname>Stern</surname><given-names>SA</given-names></name><name><surname>Storer</surname><given-names>DL</given-names></name><name><surname>van Loveren</surname><given-names>HR</given-names></name><name><surname>Hurst</surname><given-names>JM</given-names></name><etal/></person-group><article-title>Out-of-hospital administration of mannitol to head-injured patients does not change systolic blood pressure</article-title><source>Acad Emerg Med.</source><year>1996</year><volume>3</volume><fpage>840</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1111/j.1553-2712.1996.tb03528.x</pub-id><pub-id pub-id-type="pmid">8870755</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>BattisonC</surname><given-names>APJ</given-names></name><name><surname>GrahamC</surname><given-names>PT</given-names></name></person-group><article-title>Randomized, controlled trial on the effect of a 20&#x000a0;% mannitol solution and 7.5&#x000a0;% saline/6&#x000a0;% dextran solution on increased intracranial pressure after brain injury</article-title><source>Crit Care Med</source><year>2005</year><volume>33</volume><fpage>196</fpage><lpage>202</lpage><pub-id pub-id-type="doi">10.1097/01.CCM.0000150269.65485.A6</pub-id><pub-id pub-id-type="pmid">15644669</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cruz</surname><given-names>J</given-names></name><name><surname>Minoja</surname><given-names>G</given-names></name><name><surname>Okuchi</surname><given-names>K</given-names></name><name><surname>Facco</surname><given-names>E</given-names></name></person-group><article-title>Successful use of the new high-dose mannitol treatment in patients with Glasgow coma scale scores of 3 and bilateral abnormal pupillary widening: a randomized trial</article-title><source>J Neurosurg.</source><year>2004</year><volume>100</volume><fpage>376</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.3171/jns.2004.100.3.0376</pub-id><pub-id pub-id-type="pmid">15035271</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>T</given-names></name><name><surname>Quan</surname><given-names>K</given-names></name><name><surname>Cai</surname><given-names>J</given-names></name></person-group><article-title>Clinical study on application of 3&#x000a0;% hypertonic saline in treatment of severe traumatic brain injury with different administration methods</article-title><source>J J Traumatic.</source><year>2011</year><volume>16</volume><fpage>433</fpage><lpage>6</lpage></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiu</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>G</given-names></name></person-group><article-title>Clinical studies in patients with traumatic brain injury intracranial pressure with 20&#x000a0;% piracetam</article-title><source>Chin J Clin Neur.</source><year>2011</year><volume>16</volume><fpage>553</fpage><lpage>4</lpage></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Z</given-names></name></person-group><article-title>Observation of oxygen utilization of using dehydrating agent for severe traumatic brain injury</article-title><source>J Clin Emerg.</source><year>2008</year><volume>9</volume><fpage>111</fpage><lpage>3</lpage></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jianling</surname><given-names>LI</given-names></name></person-group><article-title>Clinical observation of piracetam injection to reduce of 286 patients of raised intracranial pressure</article-title><source>Xinjiang Med.</source><year>2012</year><volume>42</volume><fpage>88</fpage><lpage>9</lpage></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deng</surname><given-names>R</given-names></name><name><surname>Fan</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name></person-group><article-title>Effects of glycerol fructose or mannitol in treating intracranial hypertension induced by craniocerebral injury</article-title><source>J Med Res.</source><year>2010</year><volume>39</volume><fpage>98</fpage><lpage>100</lpage></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jianke</surname><given-names>LI</given-names></name></person-group><article-title>Glycerin fructose and mannitol treatment after craniocerebral injury of intracranial pressure clinical curative effect analysis</article-title><source>Chin Foreign Treatment.</source><year>2013</year><volume>8</volume><fpage>108</fpage><lpage>10</lpage></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>Z-G</given-names></name><name><surname>Gong</surname><given-names>Y</given-names></name><name><surname>Zhou</surname><given-names>M-H</given-names></name></person-group><article-title>Clinical observation of hypertonic sodium chloride hydroxyethyl starch 40 injection in treating traumatic brain injury</article-title><source>Modern Med J.</source><year>2011</year><volume>39</volume><fpage>149</fpage><lpage>52</lpage></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>Y-B</given-names></name><name><surname>Jiang</surname><given-names>Y-G</given-names></name><name><surname>Zhang</surname><given-names>L-Y</given-names></name></person-group><article-title>Curative effect of hypertonic saline on severe traumatic brain injury with shock</article-title><source>J Trauma Surg.</source><year>2007</year><volume>9</volume><fpage>211</fpage><lpage>4</lpage></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname><given-names>Y-F</given-names></name><name><surname>Yao</surname><given-names>H-B</given-names></name><name><surname>Shen</surname><given-names>X</given-names></name></person-group><article-title>Hypertonic saline for the treatment of intracranial hypertension due to traumatic brain edema</article-title><source>J Trauma Surg.</source><year>2013</year><volume>15</volume><fpage>296</fpage><lpage>300</lpage></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lian</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>R-Z</given-names></name><name><surname>Ren</surname><given-names>Z-Y</given-names></name></person-group><article-title>Clinical study of Kangrong injection on high intracranial pressure in patients with intracranial diseases</article-title><source>Chin J Clin Neuro Surg.</source><year>2006</year><volume>11</volume><fpage>734</fpage><lpage>6</lpage></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Long</surname><given-names>R-F</given-names></name><name><surname>Xiao-lin</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>Y-F</given-names></name></person-group><article-title>Clinical analysis of continuous infusion of 10&#x000a0;% hypertonic saline in the treatment of traumatic intracranial hypertension</article-title><source>Hainan Med J.</source><year>2011</year><volume>22</volume><fpage>9</fpage><lpage>11</lpage></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deng</surname><given-names>Q</given-names></name></person-group><article-title>Clinical application of piracetam injection to reduce intracranial pressure</article-title><source>Guide Chin Med.</source><year>2010</year><volume>8</volume><fpage>124</fpage><lpage>5</lpage></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yao</surname><given-names>Z-G</given-names></name><name><surname>Sun</surname><given-names>XL</given-names></name><name><surname>Xi</surname><given-names>Z-Q</given-names></name></person-group><article-title>Clinical observation of curative effect of 7.5 % hypertonic saline solution on patients with severe craniocerebral injury</article-title><source>Chin J Clin Neuro Surg</source><year>2008</year><volume>13</volume><fpage>205</fpage><lpage>7</lpage></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>B</given-names></name><name><surname>Huo</surname><given-names>L</given-names></name><etal/></person-group><article-title>Clinical analysis of using hypertonic saline to rescue 32 cases of patients with acute intracranial hypertension</article-title><source>Clin Med Chin.</source><year>2005</year><volume>21</volume><fpage>534</fpage><lpage>5</lpage></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>HP</given-names></name><name><surname>Kelly</surname><given-names>JR</given-names></name><name><surname>McWhorter</surname><given-names>JM</given-names></name></person-group><article-title>Comparison of mannitol regiments in patients with severe head injury undergoing intracranial monitoring</article-title><source>Jc Neurosurg.</source><year>1986</year><volume>65</volume><fpage>820</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.3171/jns.1986.65.6.0820</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nordby</surname><given-names>HK</given-names></name><name><surname>Nesbakken</surname><given-names>R</given-names></name></person-group><article-title>The effect of high dose barbiturate decompression after severe head injury. a controlled clinical trial</article-title><source>Acta Neurochir (Wien)</source><year>1984</year><volume>72</volume><fpage>157</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.1007/BF01406868</pub-id><pub-id pub-id-type="pmid">6382945</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vialet</surname><given-names>R</given-names></name><name><surname>Alban&#x000e8;se</surname><given-names>J</given-names></name><name><surname>Thomachot</surname><given-names>L</given-names></name></person-group><article-title>Isovolume hypertonic solutes (sodium chloride or mannitol) in the treatment of refractory posttraumatic intracranial hypertension: 2 mL/kg 7.5 % saline is more effective than 2 mL/kg 20 %</article-title><source>Crit Care Med</source><year>2003</year><volume>31</volume><fpage>1683</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1097/01.CCM.0000063268.91710.DF</pub-id><pub-id pub-id-type="pmid">12794404</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harutjunyan</surname><given-names>L</given-names></name><name><surname>Holz</surname><given-names>C</given-names></name><name><surname>Rieger</surname><given-names>A</given-names></name><name><surname>Menzel</surname><given-names>M</given-names></name><name><surname>Grond</surname><given-names>S</given-names></name><name><surname>Soukup</surname><given-names>J</given-names></name></person-group><article-title>Efficiency of 7.2&#x000a0;% hypertonic saline hydroxyethy/starch 200/0.5 versus mannitol 15&#x000a0;% in the treatment of increased intracranial pressure in neurosurgical patients - a randomized clinical trial</article-title><source>Crit Care.</source><year>2005</year><volume>9</volume><fpage>R530</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1186/cc3767</pub-id><pub-id pub-id-type="pmid">16277715</pub-id></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Francony</surname><given-names>G</given-names></name><name><surname>Fauvage</surname><given-names>B</given-names></name><name><surname>Falcon</surname><given-names>D</given-names></name><name><surname>Canet</surname><given-names>C</given-names></name><name><surname>Dilou</surname><given-names>H</given-names></name><name><surname>Lavagne</surname><given-names>P</given-names></name><etal/></person-group><article-title>Equimolar doses of mannitol and hypertonic saline in the treatment of increased intracranial pressure</article-title><source>Crit Care Med.</source><year>2008</year><volume>36</volume><fpage>795</fpage><lpage>800</lpage><pub-id pub-id-type="doi">10.1097/CCM.0B013E3181643B41</pub-id><pub-id pub-id-type="pmid">18209674</pub-id></element-citation></ref><ref id="CR52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cottenceau</surname><given-names>V</given-names></name><name><surname>Masson</surname><given-names>F</given-names></name><name><surname>Mahamid</surname><given-names>E</given-names></name><name><surname>Petit</surname><given-names>L</given-names></name><name><surname>Shik</surname><given-names>V</given-names></name><name><surname>Sztark</surname><given-names>F</given-names></name><etal/></person-group><article-title>Comparison of effects of equiosmolar doses of mannitol and hypertonic saline on cerebral blood flow and metabolism in traumatic brain injury</article-title><source>J Neurotrauma.</source><year>2011</year><volume>28</volume><fpage>2003</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1089/neu.2011.1929</pub-id><pub-id pub-id-type="pmid">21787184</pub-id></element-citation></ref><ref id="CR53"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hongke</surname><given-names>Z</given-names></name><name><surname>Hui</surname><given-names>LI</given-names></name></person-group><article-title>The use of 23.4&#x000a0;% hypertonic saline in the treatment of intracranial hypertension</article-title><source>Chin J Emerg Med</source><year>2002</year><volume>11</volume><fpage>176</fpage><lpage>8</lpage></element-citation></ref><ref id="CR54"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zeng</surname><given-names>H</given-names></name><name><surname>Deng</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name></person-group><article-title>Clinical analysis of using 10&#x000a0;% hypertonic saline in treatment of acute cerebrovasvular diseases</article-title><source>Chin J Emerg Med.</source><year>2007</year><volume>16</volume><fpage>155</fpage><lpage>7</lpage></element-citation></ref><ref id="CR55"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heng</surname><given-names>Y</given-names></name><name><surname>Hongke</surname><given-names>Z</given-names></name><name><surname>Hui</surname><given-names>L</given-names></name></person-group><article-title>Clinical studies of continuous use 23.4 % hypertonic saline treatment of intracranial hypertension</article-title><source>Guangdong Med J</source><year>2005</year><volume>26</volume><fpage>483</fpage><lpage>4</lpage></element-citation></ref><ref id="CR56"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zeng</surname><given-names>H</given-names></name><name><surname>Ye</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><etal/></person-group><article-title>The infection different degree intracranial hypertension by 23.4&#x000a0;% hypertonic saline. Lingnan</article-title><source>J Emerg Med</source><year>2004</year><volume>9</volume><fpage>83</fpage><lpage>5</lpage></element-citation></ref></ref-list></back></article>